Human IGFBP-4 Antibody Summary
Accession # AAA62670
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
IGFBP‑4 Inhibition of IGF‑II-dependent Cell Proliferation and Neutralization by Human IGFBP‑4 Antibody. Recombinant Human IGFBP-4 (Catalog # 804-GB) inhibits Recombinant Human IGF-II (Catalog # 292-G2) induced proliferation in the MCF-7 human breast cancer cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Human IGF-II (14 ng/mL) activity elicited by Recombinant Human IGFBP-4 (0.3 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human IGFBP-4 Monoclonal Antibody (Catalog # MAB804). The ND50 is typically 10-40 µg/mL.
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Human IGF binding protein 4 (IGFBP-4) was isolated from human plasma based on its ability to bind immobilized IGF-I. Human IGFBP-4 cDNA encodes a 258 amino acid (aa) precursor protein with a predicted 21 aa signal peptide that is processed to generate the 237 aa mature human IGFBP-4. The human IGFBP-4 contains a potential N-linked glycosylation site and shares approximately 90% aa sequence identity with both the mouse and rat IGFBP-4. According to the nomenclature of IGFBPs defined at the 4th International Symposium of IGFs (1997, Tokyo), six high-affinity IGF binding proteins (IGFBP-1, -2, -3, -4, -5, -6) and four IGFBP-related proteins (IGFBPr-1, - 2, -3, -4) have been identified. All IGFBPs have a high cysteine content and share conserved cysteine residues that are clustered in the amino- and carboxy-terminal third of the molecule. IGFBPs have been shown to either inhibit or enhance the biological activities of IGF, or act in an IGF-independent manner. Post-translational modification of IGFBPs, including phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins for IGF and may indirectly regulate IGF actions.
- Jones, J. I. and D.R. Clemons (1995) Endocrine Rev. 16:3.
- Kelly, K.M. et al. (1996) Intl. J. Biochem. Cell Biol. 28:619.
- Kim, H-S. et al. (1997) Proc. Natl. Acad. Sci. USA 94:12981.
Citation for Human IGFBP-4 Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailability.
Authors: Nakamura M, Miyamoto S, Maeda H, Ishii G, Hasebe T, Chiba T, Asaka M, Ochiai A
Biochem. Biophys. Res. Commun., 2005;333(3):1011-6.
Sample Types: Recombinant Protein
Applications: Western Blot
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human IGFBP-4 Antibody
There are currently no reviews for this product. Be the first to review Human IGFBP-4 Antibody and earn rewards!
Have you used Human IGFBP-4 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image